Abstract
In their otherwise informative review of new developments in the diagnosis and treatment of acute myeloid leukemia (AML), Löwenberg and colleagues (Sept. 30 issue)1 state that before the 1970s, the five-year survival rate among patients with AML was less than 15 percent but that survival among patients under the age of 65 years is currently 40 percent. These statistics differ markedly from U.S. population–based survival rates among patients with AML from the Surveillance, Epidemiology, and End Results (SEER) program of the National Cancer Institute,2 a consortium of 11 geographically defined cancer registries. Data from the SEER program indicate that five-year overall (observed) survival among all patients with AML was 5 percent for patients given a diagnosis in the mid-1970s, the earliest period for which data are available ( Table 1 ). Although this survival rate has improved steadily over time, it reached only 11 percent for patients given a diagnosis in the most recent years for which five-year follow-up is complete (1988 to 1991). Moreover, for patients under the age of 65, the most recent five-year survival rate was 21 percent, according to the data from the SEER program — about half that cited for this age group by Löwenberg and colleagues (although they did not specify whether they were reporting a five-year overall rate).